Inhibition of tachykinin NK₁ receptor using aprepitant induces apoptotic cell death and G1 arrest through Akt/p53 axis in pre-B acute lymphoblastic leukemia cells

详细信息    查看全文

• 作者：Samaneh Bayati^a ; ^b ; Davood Bashash^c ; Shahin Ahmadian^a ; ^{sh.ahmadian@ut.ac.ir" class="auth_mail" title="E-mail the corresponding author} ; Ava Safaroghli-Azar^c ; Kamran Alimoghaddam^b ; Ardeshir Ghavamzadeh^b ; Seyed H. Ghaffari^b ; ^{shghaffari200@yahoo.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Acute lymphoblastic leukemia ; Aprepitant ; P53 ; Nalm-6 cells ; Tachykinin NK1 receptor
• 刊名：European Journal of Pharmacology
• 出版年：2016
• 出版时间：15 November 2016
• 年：2016
• 卷：791
• 期：Complete
• 页码：274-283
• 全文大小：3781 K

文摘

Increasing number of genetic and cancer biology studies indicated a prominent role for tachykinin NK₁ receptor (NK₁R) in cancer cell growth and survival. Considering the fact that neoplastic lymphoid precursors in acute lymphoblastic leukemia (ALL) carry a three- to four-fold NK₁R expression as compared to normal lymphocytes, using NK₁R antagonist seems to be noteworthy in the treatment of ALL patients. In this study, we found that inhibition of NK₁R with aprepitant, a selective high-affinity antagonist of the human NK₁R, exerts cytotoxic and anti-proliferative effects against pre-B ALL-derived Nalm-6 cells either as single drug or in combination with doxorubicin. Our data showed that treatment of the cells with the inhibitor resulted in apoptotic cell death, at least partly, through abrogation of PI3K/Akt pathway, as revealed by the reduction of phospho/total Akt ratio. In agreement with the inhibitory effect on Akt, we also found that aprepitant increased the expression level of p21 and p27, which in turn leads to the induction of G1 cell cycle arrest. Overall, this study recommends mechanistic pathways by which inhibition of NK₁R can augment apoptotic cell death through a plausible p53-dependent pathway rather than NF-κB-depended mechanism in pre-B ALL cells; however, further studies are needed to better characterize the application of NK₁R inhibition in clinical cancer treatment.